Amodio V et al. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. Cancer Cell 2023;4(7):100908. Abstract
Anandappa G, Overman MJ. Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer. Cell Rep Med 2023;4(1):100908. Abstract
Bartley AN et al. Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: Guideline from the College of American Pathologists in collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med 2022;146(10):1194-210. Abstract
Colle R et al. BRAFV600E/RAS mutations and Lynch syndrome in patients with MSI-H/dMMR metastatic colorectal cancer treated with immune checkpoint inhibitors. Oncologist 2023;[Online ahead of print]. Abstract
Diaz Jr LA et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022;23(5):659-70. Abstract
Fox D et al. Immunotherapy for localized MSI-H colorectal cancer: Characterizing endoscopic and imaging response. ASCO 2023;Abstract 3610.
Fucà G et al. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer 2022;10(2):e004001. Abstract
Higbie VS et al. Antibiotic exposure does not impact immune checkpoint blockade response in MSI-H/dMMR metastatic colorectal cancer: A single-center experience. Oncologist 2022;27(11):952-7. Abstract
Kotani D et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29(1):127-34. Abstract
Kothari A et al. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg 2022;109:489-92. Abstract
Lenz H-J et al. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142. ASCO 2023;Abstract 3550
Lima CMSPR et al. Colorectal cancer metastatic dMMR immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610 142. ASCO 2022;Abstract TPS3647.
Ludford K et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol 2023;41(12):2181-90. Abstract
Nasca V et al. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. J Immunother Cancer 2023;11(1):e005493. Abstract
Newhook TE et al. Prospective study of perioperative circulating tumor DNA dynamics in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2022;[Online ahead of print]. Abstract
Oki E et al. Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan. ASCO 2023;Abstract 3521.
Prager GW et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 2023;388(18):1657-67. Abstract
Raghav KP et al. A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. Gastrointestinal Cancers Symposium 2023;Abstract 140.
Shen C et al. Overall survival in phase 3 clinical trials and the surveillance, epidemiology, and end results database in patients with metastatic colorectal cancer, 1986-2016 a systemic review. JAMA Newt Open 2022;5(5):e2213588. Abstract
Simmons K et al. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. ASCO 2022;Abstract 3585.
Strickler JH et al. Primary Analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. ESMO 2022;Abstract LBA2.
Tabernero J et al. BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC). ESMO 2022;Abstract LBA26.
Vikas P et al. Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline. J Clin Oncol 2023;41(10):1943-8. Abstract
Yamazaki K et al. Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial. ASCO 2023;Abstract 3508.
Yoshino T et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. ASCO 2022;Abstract LBA1.
Zeineddine FA et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. JPN Precis Oncol 2023;7(1):16. Abstract
Zhu M et al. Understanding suboptimal response to immune checkpoint inhibitors. Adv Biol (Weinh) 2023;7(4):e2101319. Abstract